Abstract

The overall objective of the Biostatistics and Bioinformatics Core (Core B) is to provide comprehensive expertise in biostatistical analysis, research design, and informatics to all participants of the SPORE in Prostate Cancer at Northwestern University, University of Chicago and NorthShore University HealthSystem.
The Specific Aims of the Core are: ? Specific Aim 1: To maintain and enhance the pre-clinical, clinical and tissue databases of the SPORE ? Specific Aim 2: To provide state of the art experimental design, epidemiological and biostatistical expertise to all of the SPORE projects ? Specific Aim 3: To conduct data collection and data analysis for SPORE projects ? Specific Aim 4: To provide infrastructure and expertise for inter-SPORE and other scientific collaborations.

Public Health Relevance

Biostatistics and Bioinformatics Core PROJECT NARRATIVE: The Core will provide expertise in study design, research methods, data quantification, statistical methods and statistical computing. This Core will work closely with all SPORE personnel in the preparation of papers for presentation and manuscripts for publication.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA180995-04
Application #
9533483
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost

  Institution

Name
Northwestern University at Chicago
Department
Type
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611

  Publications

Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652
Szmulewitz, Russell Z; Peer, Cody J; Ibraheem, Abiola et al. (2018) Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 36:1389-1395
Fong, Ka-Wing; Zhao, Jonathan C; Song, Bing et al. (2018) TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression. Nat Commun 9:5007
Giri, Veda N; Knudsen, Karen E; Kelly, William K et al. (2018) Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol 36:414-424
Anker, Jonathan F; Mok, Hanlin; Naseem, Anum F et al. (2018) A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer. J Vis Exp :
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Pascal, Laura E; Wang, Yao; Zhong, Mingming et al. (2018) EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer. Neoplasia 20:351-363
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Anker, Jonathan F; Naseem, Anum F; Mok, Hanlin et al. (2018) Multi-faceted immunomodulatory and tissue-tropic clinical bacterial isolate potentiates prostate cancer immunotherapy. Nat Commun 9:1591
Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207

Showing the most recent 10 out of 67 publications